Evidence map›Paper›PMID 31573977›Full record

ArticleJCI insight2019

Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians.

Farsad Afshinnia, Viji Nair, Jiahe Lin, Thekkelnaycke M Rajendiran, Tanu Soni, Jaeman Byun, Kumar Sharma, Patrice E Fort, Thomas W Gardner, Helen C Looker and 6 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in JCI insight, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00340678 (Renoprotection in Early Diabetic Nephropathy in Pima Indians), which is not on this map. Cited by 90 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00340678 phase3completednot on this map

Renoprotection in Early Diabetic Nephropathy in Pima Indians

TypeinterventionalSponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Ran1995 to 2014Enrolled170ConditionsDiabetic NephropathyArmsLosartan, Placebo
3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 2 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Urinary biomarkers of diabetic kidney disease.World journal of diabetes · 2026
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Diabetic retinal disease.Nature reviews. Disease primers · 2025
    Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Farsad AfshinniaDivision of Nephrology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Viji NairDivision of Nephrology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Jiahe LinDepartment of Statistics, University of Michigan, Ann Arbor, Michigan, USA.
Thekkelnaycke M RajendiranMichigan Regional Comprehensive Metabolomics Resource Core and.
Tanu SoniMichigan Regional Comprehensive Metabolomics Resource Core and.
Jaeman ByunDivision of Nephrology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Kumar SharmaDivision of Nephrology, Department of Internal Medicine, University of Texas Health at San Antonio, San Antonio, Texas, USA.
Patrice E FortDepartment of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Thomas W GardnerDepartment of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Helen C LookerChronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, USA.
Robert G NelsonChronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, USA.
Frank C BrosiusDivision of Nephrology, Department of Medicine, University of Arizona College of Medicine, Tuscan, Arizona, USA.
Eva L FeldmanDepartment of Neurology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
George MichailidisDepartment of Statistics and.
Matthias KretzlerDivision of Nephrology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Subramaniam PennathurDivision of Nephrology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
University of Michigan · USNational Institute of Diabetes and Digestive and Kidney Diseases · USThe University of Texas Health Science Center at San Antonio · USUniversity of Arizona · USUniversity of Florida · US

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Scott Soleimanpour · 2013 to 2026
$24.3M
Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Karen Eileen Peterson · 2010 to 2026
$20.3M
Integrated Systems Biology Approach to Diabetic Microvascular ComplicationsR24DK082841 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ABCOUWER, STEVEN F, BROSIUS, FRANK C · 2008 to 2020
$13.1M
University of Michigan O'Brien Kidney Translational Core CenterP30DK081943 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PENNATHUR, SUBRAMANIAM · 2008 to 2022
$12.9M
Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
Spatial Multi-Omics to Profile Metabolic Pathways for Kidney DiseaseU01DK114920 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Christopher R Anderton, Kumar Sharma · 2022 to 2026
$3.9M
Prognostic Biomarkers in Chronic Kidney DiseaseK08DK106523 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI AFSHINNIA, FARSAD · 2015 to 2019
$789k
Lipidomic Predictors of Diabetic Kidney Disease Progression in Patients with Type-1 DiabetesR03DK121941 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI AFSHINNIA, FARSAD · 2019 to 2020
$169k
NIDDK NIH HHS K08 DK106523NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK081943NIDDK NIH HHS P30 DK089503NIDDK NIH HHS P30 DK092926NIDDK NIH HHS R03 DK121941NIDDK NIH HHS R24 DK082841NIDDK NIH HHS U01 DK114920
6 · The paper itself

Abstract

BACKGROUNDIn this study, we identified the lipidomic predictors of early type 2 diabetic kidney disease (DKD) progression, which are currently undefined.METHODSThis longitudinal study included 92 American Indians with type 2 diabetes. Serum lipids (406 from 18 classes) were quantified using mass spectrometry from baseline samples when iothalamate-based glomerular filtration rate (GFR) was at least 90 mL/min. Affymetrix GeneChip Array was used to measure renal transcript expression. DKD progression was defined as at least 40% decline in GFR during follow-up.RESULTSParticipants had a mean age of 45 ± 9 years and median urine albumin/creatinine ratio of 43 (interquartile range 11-144). The 32 progressors had significantly higher relative abundance of polyunsaturated triacylglycerols (TAGs) and a lower abundance of C16-C20 acylcarnitines (ACs) (P < 0.001). In a Cox regression model, the main effect terms of unsaturated free fatty acids and phosphatidylethanolamines and the interaction terms of C16-C20 ACs and short-low-double-bond TAGs by categories of albuminuria independently predicted DKD progression. Renal expression of acetyl-CoA carboxylase-encoding gene (ACACA) correlated with serum diacylglycerols in the glomerular compartment (r = 0.36, and P = 0.006) and with low-double-bond TAGs in the tubulointerstitial compartment (r = 0.52, and P < 0.001).CONCLUSIONCollectively, the findings reveal a previously unrecognized link between lipid markers of impaired mitochondrial β-oxidation and enhanced lipogenesis and DKD progression in individuals with preserved GFR. Renal acetyl-CoA carboxylase activation accompanies these lipidomic changes and suggests that it may be the underlying mechanism linking lipid abnormalities to DKD progression.TRIAL REGISTRATIONClinicalTrials.gov, NCT00340678.FUNDINGNIH R24DK082841, K08DK106523, R03DK121941, P30DK089503, P30DK081943, and P30DK020572.

Indexed as

Indians, North AmericanLipogenesisAdultDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionFemaleGlomerular Filtration RateHumansLongitudinal StudiesMaleMiddle AgedOxidation-ReductionPrognosisChronic kidney diseaseDiabetesFatty acid oxidationMetabolismNephrology

Identifiers

PMID31573977
PMCPMC6948762
OpenAlexW2978061158

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.